{"id":"W2620746860","doi":"10.1056/nejmoa1702900","title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1772,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"Medical Research Council; Cardiff University; University of Glasgow; Swansea University; University of Sussex; King's College London; National Institute for Health and Care Research; University College London; Cancer Research UK; Royal Marsden NHS Foundation Trust","keywords":"Abiraterone acetate; Prostate cancer; Abiraterone; Androgen deprivation therapy; Medicine; Oncology; Internal medicine; Testosterone (patch); Cancer; Prostate; Hormone therapy; Prednisolone; Urology; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05415089647709481,"score_gpt":0.3600978921108623,"score_spread":0.3059469956337675,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}